1. At a Glance – Small Cap, Big Drama
Quest Laboratories Ltd is currently sitting at ₹121 with a market cap of ₹198 crore. In the last 3 months, the stock is up 39.1%, but over one year, it’s still down 12%. So yes, this stock has mood swings.
Now the juicy part — Q3 FY26 numbers.
Sales came in at ₹30.61 crore, up 106% YoY. PAT jumped to ₹4.03 crore, up 417% YoY. That’s not growth. That’s a protein shake.
Stock P/E stands at 14. ROE is 24.6%. ROCE is 26.9%. Debt-to-equity is just 0.36. Price-to-book is 2.20.
For an SME pharma company doing ₹126 crore TTM revenue and ₹14.1 crore PAT, these are not ugly numbers.
But here’s the twist — earnings include ₹7.25 crore of other income in TTM.
So the question is simple: Is Quest Laboratories a quietly compounding pharma story… or is it riding a one-time boost wave?
Let’s investigate like a slightly sarcastic detective.
2. Introduction – The Pharma Kid from Pithampur
Quest Laboratories was incorporated in 1998. No dramatic origin story. No Silicon Valley garage. Just good old pharmaceutical manufacturing in Pithampur, Dhar.
This is not a flashy branded pharma giant like Sun Pharma or Cipla. This is the backend workhorse — making formulations across antibiotics, anti-malarials, anti-inflammatories, respiratory meds, diabetes treatments, and more.
They produce:
- Tablets
- Syrups
- Dry syrups
- Ointments
- ORS powders
- External liquids
Over 800+ licensed formulations and 272+ active products.
They operate across OTC, ethical, generic, institutional supplies, contract manufacturing, exports, and PCD business.
Translation: They don’t want to miss any revenue bucket.
They even have a ₹25 crore order book from Myanmar.
Now pause.
An SME pharma company with export orders, new injectable plant plans, capsule section launch, collagen launch, and capex of ₹35 crore over 3 years?
Ambitious much?
Or building something real?
3. Business Model – WTF Do They Even Do?
Okay, imagine you’re a hospital, a government institution, or an export distributor in Myanmar.
You need:
- Antibiotics
- Antimalarials
- Diabetes drugs
- Respiratory meds
- ORS powders
- Generic formulations
Quest manufactures them.
Simple.
They sell 61% revenue from tablets, 19% from syrups, 10% from ORS, 8% from suspensions, and 2% from ointments (FY24 breakup).
Sectorally:
- 81% revenue from public institutions
- 19% from private enterprises
This means government tenders matter.
And if you understand Indian pharma tenders, you know two things:
- Volume is high.
- Margins are tight.
But they’re now expanding into:
- Capsules (10 lakh per day capacity, ₹10–15 crore expected annual contribution)
- Injectables (2 lakh/day capacity, ₹30 crore expected annual revenue)
- Collagen (launch April 1, 2025)
Injectables are margin-enhancing products. That’s not small news.
Current capacity is already strong:
- 9 million+ tablets per day
- 1 million+ capsules per day (upcoming full scale)
- 30,000+ dry syrups daily
- 2,000+ liters external liquids daily
So they’re not tiny in operations. Just tiny in market cap.
Now the real question:
Can they scale without losing margins?
Let’s check numbers.
4. Financials Overview – Numbers Don’t Lie (Mostly)
Quarterly Results – Figures in ₹ Crores
EPS:
